The primary objective is generation of functional neuronal networks from induced pluripotent stem cells (iPSCs) derived from patients with ischemic stroke. The secondary objectives are to measure neuronal network responses to simulated cerebral…
ID
Source
Brief title
Condition
- Central nervous system vascular disorders
Synonym
Research involving
Sponsors and support
Intervention
Outcome measures
Primary outcome
Primary outcome measure is network functionality, where a network is considered
functional when a minimum of 1/3 of the electrodes shows activity, with a
minimum of 6 spikes per minute per active electrode, and a minimum of one
synchronous event per minute at eight weeks after plating.
Secondary outcome
- Electrophysiological responses to simulated *cerebral ischemia*
- Network and neuronal properties as studied by immunocytochemical analyses.
Background summary
To identify new, individualized, neuroprotective treatments for ischemic
stroke, responses to ischemia of human neurons, including inter-individual
variation, need clarification. By combining state of the art stem cell biology
and organ-on-a-chip technology, we aim to derive neuronal networks of patients
with brain infarcts and investigate the effects of simulated cerebral ischemia.
Ultimately, we aim to identify new, individualized treatment targets.
Study objective
The primary objective is generation of functional neuronal networks from
induced pluripotent stem cells (iPSCs) derived from patients with ischemic
stroke. The secondary objectives are to measure neuronal network responses to
simulated cerebral ischemia, estimate differences between patients and
controls, and estimate variation amongst patients.
Study design
A prospective, experimental, case-control study in human blood.
Collection of heparin diluted blood samples (30cc per subject). Blood samples
will be used for derivation of neuronal networks in the laboratory. All
subsequent experiments are with these neuronal networks in the lab. Patients
will be treated according to local and national guideline for ischemic stroke.
There will be no experimental / additional treatment for patients. Standard
treatment or care will not be withheld.
Study burden and risks
Risks of blood sampling are considered negligible.
Wagnerlaan 55
Arnhem 6815 AD
NL
Wagnerlaan 55
Arnhem 6815 AD
NL
Listed location countries
Age
Inclusion criteria
* Age * 18y
* Clinical and radiological diagnosis of acute ischemic stroke
* Admission to stroke unit
* Capability to provide written informed consent
Exclusion criteria
* Any relevant systemic disease that is expected to interfere with a patient
outcome within six months, such as malignancy
* Any progressive neurodegenerative disease
* Severe aphasia (informed consent not possible)
Design
Recruitment
Followed up by the following (possibly more current) registration
No registrations found.
Other (possibly less up-to-date) registrations in this register
No registrations found.
In other registers
| Register | ID |
|---|---|
| CCMO | NL72176.091.19 |